TNFRSF4 and neoplasm: Preclinical data indicatethat intratumoral aOX40 administration, in addition to its stimulatoryeffects on T cells via OX40 agonism, causes activating Fc receptor-dependentTreg depletion in the tumor, further underscoring the opportunitiesavailable to engineer therapeutic antibodies to simultaneously stimulateeffector T cells while also depleting Tregs following intratumoraladministration.80